MedTrace Logo

Feasibility, Acceptability and Costs of a Multiple First-lines Artemisinin-based Combination Therapies

NCT04265573 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150000

Last updated 2022-03-25

No results posted yet for this study

Summary

A simultaneous deployment of multiple first line therapies (MFT) for uncomplicated malaria using artemisisin based combination therapies as showed by theoretical models, may extend the useful therapeutic life of the current Artemisinin-based combination thérapies (ACTs) by reducing drug pressure and slowing the spread of resistance without putting life at risk. We therefore hypothesized that a simultaneous deployment of three ACTs targeting three segments of the population is feasible, acceptable and can achieve high coverage rate if potential barriers are well identified, well addressed and the key implementers are well-trained and adequately supported. To test this hypothesis, a quasi-experimental study will be conducted.

Conditions

Sponsors & Collaborators

  • Medicines for Malaria Venture

    collaborator OTHER

  • National Malaria Control Programme (NMCP), Burkina Faso

    collaborator UNKNOWN

  • Institut de Recherche en Sciences de la Sante, Burkina Faso

    collaborator OTHER_GOV

  • Groupe de Recherche Action en Sante

    lead OTHER

Principal Investigators

  • Mohamadou Siribié, MD, PhD · Groupe de Recherche Action en Sante

  • André-Marie Tchouatieu, MD · Medicine for Malaria Venture (MMV)

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-10
Primary Completion
2020-12-01
Completion
2021-02-25

Countries

  • Burkina Faso

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04265573 on ClinicalTrials.gov